MannKind (NASDAQ:MNKD) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of MannKind (NASDAQ:MNKD) from a buy rating to a hold rating in a report issued on Saturday morning.

MNKD has been the topic of several other research reports. Wells Fargo & Company cut their price target on MannKind from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Friday. Truist Financial set a $9.00 price objective on shares of MannKind in a research report on Monday, November 24th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $3.50 price objective (down from $7.50) on shares of MannKind in a research report on Friday. Weiss Ratings reiterated a “hold (c)” rating on shares of MannKind in a report on Thursday, January 22nd. Finally, Leerink Partners started coverage on shares of MannKind in a report on Thursday, November 13th. They set an “outperform” rating and a $7.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.21.

MannKind Trading Up 1.2%

NASDAQ:MNKD opened at $3.28 on Friday. The firm has a 50 day moving average of $5.55 and a 200-day moving average of $5.36. MannKind has a 1 year low of $2.93 and a 1 year high of $6.51. The stock has a market capitalization of $1.01 billion, a P/E ratio of 164.08 and a beta of 0.84.

MannKind (NASDAQ:MNKD) last posted its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). The business had revenue of $111.96 million during the quarter, compared to analyst estimates of $99.85 million. MannKind had a negative return on equity of 11.12% and a net margin of 1.68%.MannKind’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.03 EPS. As a group, analysts forecast that MannKind will post 0.1 EPS for the current fiscal year.

Insider Activity

In other news, insider Stuart A. Tross sold 47,006 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $6.33, for a total transaction of $297,547.98. Following the transaction, the insider directly owned 985,007 shares of the company’s stock, valued at approximately $6,235,094.31. This trade represents a 4.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Castagna sold 65,804 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $6.01, for a total value of $395,482.04. Following the completion of the sale, the chief executive officer owned 2,504,792 shares of the company’s stock, valued at approximately $15,053,799.92. This trade represents a 2.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 262,846 shares of company stock valued at $1,546,840 in the last quarter. Corporate insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On MannKind

A number of institutional investors have recently added to or reduced their stakes in MNKD. Caitong International Asset Management Co. Ltd increased its holdings in shares of MannKind by 108.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 2,927 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of MannKind in the 4th quarter worth about $45,000. Huntington National Bank increased its holdings in MannKind by 420.0% in the fourth quarter. Huntington National Bank now owns 10,400 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 8,400 shares in the last quarter. Burkett Financial Services LLC acquired a new position in shares of MannKind during the 4th quarter valued at $59,000. Finally, Laurel Wealth Advisors LLC acquired a new position in shares of MannKind during the fourth quarter valued at about $60,000. 49.55% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.